Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, PLX9486 (anticipated name change to CGT9486), is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. PLX9486 has already exhibited promising early clinical activity and safety in a Phase 1/2 trial in patients with advanced GIST and also has the potential to full an unmet need for patients living with Systemic Mastocytosis.
Oct 05, 2020
Aug 11, 2020
Jul 6, 2020 at 10:30 AM EDT
Mar 3, 2020 from 9:20 AM to 9:50 AM EST
Dec 5, 2019 at 12:10 PM EST